Europeiska unionen - svenska - EMA (European Medicines Agency)

glaxosmithkline trading services - mepolizumab - astma - läkemedel mot obstruktiv lungsjukdom, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ipex medical ab - rrr-alfa-tokoferylacetat; askorbinsyra; dexpantenol; koffein; kolekalciferol; kolinklorid; myo-inositol; nikotinamid; pyridoxinhydroklorid; retinolpalmitat; riboflavinnatriumfosfat; tiaminhydroklorid - oral lösning - retinolpalmitat 9,87 mikrog aktiv substans; glukosmonohydrat hjälpämne; glycerol 85% hjälpämne; etanol, vattenfri hjälpämne; askorbinsyra 1,2 mg aktiv substans; sackaros hjälpämne; koffein 2 mg aktiv substans; pyridoxinhydroklorid 30 mikrog aktiv substans; rrr-alfa-tokoferylacetat 30 mikrog aktiv substans; tiaminhydroklorid 60 mikrog aktiv substans; kolinklorid 6 mg aktiv substans; kolekalciferol 0,45 mikrog aktiv substans; dexpantenol 60 mikrog aktiv substans; myo-inositol 1,2 mg aktiv substans; nikotinamid 0,6 mg aktiv substans; riboflavinnatriumfosfat 90 mikrog aktiv substans - övriga kombinationer

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

abigo medical ab - rrr-alfa-tokoferylacetat; dexpantenol; ergokalciferol; inositol; koffein; kolinklorid; natriumferedetat; nikotinamid; pyridoxinhydroklorid; retinolpalmitat; riboflavinnatriumfosfat; tiaminhydroklorid - oral lösning - ergokalciferol 0,45 mikrog aktiv substans; koffein 2 mg aktiv substans; etanol, vattenfri hjälpämne; sackaros hjälpämne; glycerol 85% hjälpämne; glukosmonohydrat hjälpämne; natriumferedetat 10 mg aktiv substans; riboflavinnatriumfosfat 90 mikrog aktiv substans; pyridoxinhydroklorid 30 mikrog aktiv substans; rrr-alfa-tokoferylacetat 30 mikrog aktiv substans; tiaminhydroklorid 60 mikrog aktiv substans; kolinklorid 6 mg aktiv substans; retinolpalmitat 36 mikrog aktiv substans; dexpantenol 60 mikrog aktiv substans; inositol 1,2 mg aktiv substans; nikotinamid 0,6 mg aktiv substans - Övriga kombinationer

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - läkemedel mot obstruktiv lungsjukdom, - allergiska asthmaxolair är indicerat hos vuxna, ungdomar och barn (6 till.

Europeiska unionen - svenska - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenter för dermatit, med undantag av kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

cis bio international - succimer - beredningssats för radioaktivt läkemedel - 1 mg - succimer 1 mg aktiv substans - teknetium(tc-99m)succimer

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

curium netherlands b.v. - succimer - beredningssats för radioaktivt läkemedel - 1,2 mg - succimer 1,2 mg aktiv substans - teknetium(tc-99m)succimer

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

viatris ab - bifidobacterium animalis; lactobacillus acidophilus; lactobacillus bulgaricus; streptococcus thermophilus - kapsel, hård - lactobacillus acidophilus 32 mg aktiv substans; bifidobacterium animalis 17 mg aktiv substans; glukos (vattenfri) hjälpämne; streptococcus thermophilus 23 mg aktiv substans; lactobacillus bulgaricus 6 mg aktiv substans - intestinala antiinflammatoriska och antiinfektiva medel

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

allergon ab - bifidobacterium lactis; lactobacillus acidophilus; lactobacillus bulgaricus - kapsel, hård - lactobacillus bulgaricus 13 mg aktiv substans; bifidobacterium lactis 7 mg aktiv substans; glukos (vattenfri) hjälpämne; lactobacillus acidophilus 18 mg aktiv substans - intestinala antiinflammatoriska och antiinfektiva medel

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

curium netherlands b.v. - indium(in-111)klorid; pentetreotid - beredningssats för radioaktivt läkemedel - 111 mbq/ml - pentetreotid 10 mikrog aktiv substans; indium(in-111)klorid 122 mbq aktiv substans - indium(in-111)pentetreotid